Bright Minds Biosciences Inc.

CNSX:DRUG Stock Report

Market Cap: CA$6.1m

Bright Minds Biosciences Balance Sheet Health

Financial Health criteria checks 6/6

Bright Minds Biosciences has a total shareholder equity of CA$6.0M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$6.9M and CA$854.2K respectively.

Key information

0%

Debt to equity ratio

CA$0

Debt

Interest coverage ration/a
CashCA$6.76m
EquityCA$6.03m
Total liabilitiesCA$854.16k
Total assetsCA$6.89m

Recent financial health updates

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Aug 19
Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Mar 07
We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Nov 04
We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Recent updates

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Aug 19
Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Mar 07
We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Nov 04
We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Financial Position Analysis

Short Term Liabilities: DRUG's short term assets (CA$6.8M) exceed its short term liabilities (CA$854.2K).

Long Term Liabilities: DRUG has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: DRUG is debt free.

Reducing Debt: DRUG has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DRUG has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: DRUG has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 32.2% each year.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.